Unilateral Axillary Lymphadenopathy in Cancer Patients Post-COVID-19 Vaccination: Review and Case Series
Open Access
- 6 April 2023
- journal article
- case report
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 194-209
Abstract
Novel coronavirus-19 (COVID-19) variants continue to spread worldwide with the development of highly transmissible strains. Several guidelines addressing management of cancer patients during the COVID-19 pandemic have been published, primarily based upon expert opinion. The COVID-19 pandemic has affected all aspects of breast cancer care including screening, diagnosis, treatment, and long-term follow-up. Recent reports indicate that mRNA COVID-19 vaccines can provoke lymphadenopathy in both cancer patients and healthy individuals. Unilateral axillary lymphadenopathy (UAL) post-COVID-19 vaccination is a challenging presentation for cancer patients because of the potential for misinterpretation as malignancy. The World Health Organization’s target to vaccinate 70% of the world’s population by mid-2023 is likely to increase the incidence of post-COVID-19 vaccination UAL. In this article, we review the published evidence regarding UAL post-COVID-19 vaccination and present diverse cases of breast cancer patients where false-positive UAL post-COVID-19 vaccination proved to be a therapeutic challenge. The United Arab Emirates (UAE) vaccination program is well ahead of other countries in the world, having accomplished the target of 100% vaccination of the population with at least one dose. Therefore, an increasing number of recently vaccinated patients are likely to present with UAL, detected by surveillance imaging, post-vaccination. We have therefore made recommendations regarding the management of cancer patients with UAL post-COVID-19 vaccination in order to avoid misdiagnosis and unnecessary imaging or invasive biopsy procedures.Keywords
This publication has 43 references indexed in Scilit:
- Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic PatientsRadiology, 2021
- COVID-19 vaccines for patients with cancer: benefits likely outweigh risksJournal of Hematology & Oncology, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 InfectionJAMA Oncology, 2021
- COVID-19-neutralizing antibodies predict disease severity and survivalCell, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsScience, 2020
- Axillary lymph node accumulation on FDG-PET/CT after influenza vaccinationAnnals of Nuclear Medicine, 2012
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009